<DOC>
	<DOCNO>NCT00003827</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill cancer cell . Chemoprotective drug amifostine may protect normal cell side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine topotecan cytarabine give amifostine treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect amifostine , topotecan , cytarabine patient poor risk myelodysplastic syndrome . - Determine hematologic response rate , cytogenetic response rate , rate polyclonal hematopoiesis follow treatment regimen . - Determine duration response time disease progression follow treatment regimen patient . OUTLINE : Patients receive topotecan continuous IV 24 hour plus cytarabine IV 2 hour , day 1-5 . Patients receive amifostine IV 15 minute every day maximum 60 day . Patients may receive second course regimen 8 week first . Patients follow least monthly 2 year , every 3-6 month death . PROJECTED ACCRUAL : Approximately 25 patient accrue study within 1 1.5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm poor risk myelodysplastic syndrome , include least one following : Bilineage cytopenia Unfavorable cytogenetic abnormality Refractory anemia excess blast and/or refractory anemia excess blast transformation ( great 5 % blast ) At least 0.5 International Prognostic Score System No chronic myelomonocytic leukemia No hypocellular myelodysplastic syndrome ( marrow cellularity le 30 % ) PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count le 1,500/mm3 Platelet count le 100,000/mm3 Hemoglobin less 10 g/dL Hepatic : ALT le 5 time upper limit normal Renal : Creatinine great 1.4 mg/dL Cardiovascular : No congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception Must right atrial catheter insert PRIOR CONCURRENT THERAPY : Biologic therapy : No prior blood bone marrow transplantation Chemotherapy : No prior acute myeloid leukemia chemotherapy ( except hydroxyurea low dose cytarabine ) No prior topotecan No prior amifostine Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 24 hour since prior antihypertensive medication prior amifostine</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>